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ZambiaObjective: To examine sales practices, knowledge, and behavior of pharmacyworkers regardingmedical abortion
in 2009 and 2011 in Zambia, where hostile and stigmatizing attitudes still result in high rates of unsafe abortion.
Methods: Four mystery clients visited pharmacies during 2009 and 2011, and recorded their experiences fol-
lowing their interactions using a standardized form. Bivariate analysis examined pharmacy workers’ attitudes,
behavior, and medical abortion-dispensing practices. Results: Mystery clients visited 76 pharmacies in 2009
and 80 pharmacies in 2011. In 2011, mystery clients reported hostile interactions with pharmacy workers
at 8 (10%) pharmacy visits, a relative decrease from 7 (22%) in 2009 (P = 0.0353). In 2009, less than half
(35 [46%]) of clients received information or had the opportunity to purchasemedical abortion drugs in compar-
ison with 53 (66%) in 2011 (P= 0.0110). In 2011, more pharmacy workers mentioned a valid medical abortion
drug in comparison with 2009 (42 [53%] vs 31 [41%], respectively); however, guidance for women onmisopros-
tol use was minimal. Conclusion: Pharmacy workers exhibited increased awareness of misoprostol, less hostility,
and a willingness to sell medical abortion drugs; however, they continued to provide inadequate information on
misoprostol for medical abortion. Effective training of pharmacy employees is vital in increasing access to safe
induced-abortion care.
© 2015 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Globally, the World Health Organization (WHO) estimates that
22 million unsafe abortions occur each year, resulting in the death
of nearly 47 000 women [1]. In East Africa alone, the annual number
of unsafe abortionswas almost 2.5million in 2008 [2], whichwere asso-
ciated with almost 17% of the region’s maternal deaths [3]. Even as
countries continue to decrease legal restrictions that penalize women
and providers [4], unsafe abortion remains a daunting problem, causing
disproportionate suffering in the poorest countries and among the
poorest families in the world [5].
Despite having one of the least restrictive induced abortion laws in
Sub-Saharan Africa, regulations in Zambia’s 1972 Termination of Preg-
nancy Act [6] still result in substantial barriers to safe induced abortion,
especially in rural areas where access to safe termination providers are
limited [7]. Maternal mortality, at 591 maternal deaths per 100 000 live
births, remains high [8] and one study in Zambia estimated unsafevisor, Ipas, 300 Market St., Suite
fax: +1 919 929 0258.
endrickson).
logy and Obstetrics. Published byabortion complications could account for 30% of maternal deaths [9].
The number of women admitted for post-abortion care to ﬁve major
Zambian hospitals from 2003–2008 was almost 53 000; more than
half of these complications were attributed to unsafe abortion [10].
Medical abortion, provided in health facilities or accessed bywomen
themselves in pharmacies, has been shown to contribute to a decline
in the number and severity of complications from unsafe abortions
[11–13]. Medical abortion, using mifepristone and misoprostol, was in-
troduced into Zambia in 25public health facilities in 2009. Although 78%
of eligible women seeking induced abortions chose medical abortion
between January 2010 and September 2011 [14], roll-out to additional
health facilities has been slow, being hindered by policy hurdles that
continue to impede progress in expanding access to safe and legal in-
duced abortions. In 2009, there were at least six products derived
from the drugs mifepristone (two) or misoprostol (four) that were
registered and permitted for sale in Zambia. Despite mifepristone’s
limited use in public health facilities in 2009, misoprostol variants and
their abortifacient qualities were quite widely known by women, as
well pharmacy and healthcare workers. However, these misoprostol
productswere registered for uses other thanmedical abortion (including
other gynecological uses) so information related to their abortifacientElsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
2009 2011
76 80Number of pharmacies visited
Number of pharmacists who offered 
a drug of information
Number of pharmacists who offered 
to sell a valid abortion medication
35 (46%) 53 (66%)
18 (24%) 38 (48%)
Denominator for proportions is the number of pharmacies 
visited
Fig. 1. Flow diagram showing number of pharmacies visited, those who offered a drug or
information and those who offered to sell a valid abortion medication.
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sell these products to womenwith a prescription; however, as the pack-
age inserts for these products do not contain information on the drug’s
abortifacient properties, it is unclear whether pharmacy workers know
what advice to give women about using these products to terminate a
pregnancy. This is in spite of scientiﬁc information about the efﬁcacy
and safety of these drugs, including endorsements from WHO, which
continues to grow [15]. However, medical abortion with misoprostol
alone is up to 85% effective until 10 weeks of pregnancy, and up to 85%
effective at 9–13 weeks of pregnancy when the proper dosage and regi-
men is followed [16,17].
Pharmacists and more informal drug sellers have long been the
primary sources of information and medication for the treatment and
prevention of illness [18]. They are often a convenient, anonymous
and inexpensive source of information, particularly when physicians
are in short supply [18]. In one national study conducted in Cambodia,
37% of women seeking post-abortion care reported having attempted
to terminate the pregnancy prior to visiting the clinic; 80% of these
women sought advice or assistance from someone who sold drugs
[19]. The role that pharmacy workers have in the provision of medical
abortion drugs, and their contribution to either assist women in having
a safe abortion, with adequate and correct information, or to perpetuate
unsafe abortion with a lack of information or even misinformation, is
largely unknown. In Zambia, pharmacists must study to become li-
censed pharmacists; they are degree holders and are able to own and
manage a pharmacy. Additionally, they are able to supervise pharmacy
assistants, or technologists, who do not have a degree. Pharmacists are
required to request a prescription based on the schedule of the drug
being sought. Misoprostol is a schedule II drug, which requires a pre-
scription, regardless of desired use. The aim of the present study was
to examine the sales practices, knowledge, and behavior of pharmacy
workers around medical abortion in Zambia in 2009 and 2011, a dy-
namic environment for induced-abortion care. To our knowledge, the
ﬁndings of the present study offer the ﬁrst data regarding pharmacy
practices related to the sale and use of drugs for medical abortion in
Zambia, where hostile and stigmatizing attitudes about induced abor-
tion still result in a high rate of unsafe abortions [20].
2. Materials and methods
The present study was part of a pilot study to improve abortion care
and to introduce medical abortion services in 25 public health facilities
in Zambia. A descriptive cross-sectional design was used to explore
pharmacy worker knowledge and practices in 2009 and 2011. In both
years, a complete listing of government-certiﬁed pharmacies in the
intervention areas of Lusaka, Kafue, and Copperbelt provinces was
provided by the Pharmaceutical Society of Zambia. These pharmacies
were located in a variety of settings, from urban shops in Lusaka to
small town pharmacies in the more rural areas of the Kafue and
Copperbelt provinces. Informed consent was not obtained from the
pharmacy workers because the mystery-client methodology requires
non-disclosure to the service provider; however, strict conﬁdentiality
measures were put in place to protect the pharmacy workers. Ethical
approval for this study was provided by The University of Zambia
Biomedical Research Ethics Committee and the USA-based Allendale
Investigational Review Board.
The study design incorporated two single-sample surveys of non-
independent groups; some, but not all, of the pharmacy workers who
interacted with mystery clients in 2009 may also have been in the
2011 group. Some of the pharmacists may also have been a part of a
training or technical update meeting, but the methodology does not
allow this determination to be made with certainty.
Four research assistants (two young male and two young female
mystery clients) with experience in reproductive health attempted to
visit all the pharmacies listed. Each mystery client asked the pharmacy
worker if they sold anything to induce an abortion, either for themselvesor for a girlfriend. Mystery clients were trained to explain at the start
that their (or their girlfriend’s) period was late and that it was 6 weeks
ago. Themystery clients had a list of possible probe questions to ask de-
pending on the pharmacy workers’ responses. Each mystery client re-
corded key information from the pharmacy worker–client interaction,
including behavior, on a standardized form upon leaving the pharmacy.
If the pharmacy worker offered to let them purchase something to
induce an abortion, mystery clients were instructed to ask to see the
product, to ask for information about its use and cost, and were told to
then say that they needed to return to purchase the product.
Data were entered in Epidata v3.1 (The EpiData Association, Odense,
Denmark) and were analyzed with STATA v12 (Stata, College Station,
TX, USA). A bivariate analysis was conducted to examine pharmacy
workers’ attitudes, behavior, and dispensing practices related to medi-
cal abortions and P b 0.05 was considered statistically signiﬁcant. This
study analyzed these interactions, comparing results of 76 mystery
client visits in 2009 and 80 visits in 2011 (Fig. 1).
3. Results
Mystery clients were able to visit 76 pharmacies in November 2009
and 80 inNovember 2011. It wasnot possible to obtain speciﬁc informa-
tion regarding the pharmacy attendants, the mystery clients estimated
the pharmacy workers’ ages as being either older or younger than
30 years (Table 1). A similar distribution was found in both years,
with most attendants (approximately 57%) estimated to be older than
30 years of age. In 2011,mystery clients had at least one other customer
in the store at the time they approached the pharmacy worker more
frequently than in 2009 (63 [79%] vs 33 [43%]; P b 0.001).
Despite there being other customers in the pharmaciesmore often in
2011, there was an increase in the number of pharmacy workers who
were sympathetic and interested in helping the client (Table 1). In
2011, fewer mystery clients reported that they would describe their
interactions with pharmacy workers discussing medical abortion as
hostile, decreasing from 17 (22%) to only 8 (10%) (P=0.0353). Further-
more, in 2011 there was an observed increase in pharmacy workers’
willingness to provide information about medical abortion. In 2009,
35 (46%) clients left pharmacies with more information or with the
opportunity to purchase medical abortion drugs; however, in 2011,
this proportion was higher with 53 (66%) mystery clients reporting
this (P = 0.0110). Additionally, more pharmacy workers mentioned
or recommended a valid medical abortion drug (deﬁned as a known
misoprostol or mifepristone product) in 2011 compared with 2009
(42 [53%] vs 31 [41%], respectively).
Among the pharmacy workers who explicitly offered a medical
abortion drug or information on a medical abortion drug, 3 (9%) re-
ferred mystery clients to a health facility for medical abortion in 2009,
compared with 14 (26%) in 2011 (Table 2). In both years of the study,
most pharmacy workers (31 [89%] in 2009 and 42 [79%] in 2011)
Table 1
Demographics of pharmacy workers and summary of mystery-client interactions wih
pharmacy workers.a
Pharmacy interaction 2009 study
visit (n = 76)
2011 study
visit (n = 80)
P-value
Pharmacy worker age (as estimated
by mystery client), y
0.9
30 or younger 33 (43) 34 (43)
31 or older 43 (57) 46 (58)
At least one other customer in the
store at the time of interview
33 (43) 63 (79) b0.001b
Mystery client described interaction
with pharmacy worker as hostile
17 (22) 8 (10) 0.0353b
Pharmacy worker offered to sell,
or provided information about,
medical abortion drugs
35 (46) 53 (66) 0.0110b
Pharmacy worker
mentioned/recommended
a valid medical abortion product
31 (41) 42 (53) 0.1
a Values given as number (percentage) unless otherwise noted.
b Indicates a statistically signiﬁcant difference.
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ever, a far smaller number offered to sell mystery clients these medica-
tions. Among the pharmacyworkers who offered to sell mystery clients
a drug or offered information, 18 (51%) offered to sell the client a known
and approved medical abortion drug in 2009, compared with 38 (72%)
in 2011 (P = 0.0380). Although the mystery clients in this study were
trained to probe for any and all products that were recommended
to them, all of the drugs that were mentioned or offered were either
Cytotec (Pﬁzer, New York, NY, USA) or “the Chinese pill”, known to be
a misoprostol drug imported from China. Despite the introduction of
mifepristone in the study areas, none of the pharmacy workers men-
tioned, described, or offered to sell mifepristone. In both of the study
years, a few pharmacy workers, 4 (11%) in 2009 and 11 (21%) in 2011,
said they knew of something that would help a woman start a medical
abortion but, despite the mystery clients probing on this issue, they did
not state the names of these drugs. During both study years, among
the pharmacy workers who did offer to help, approximately four in
10 mystery clients were asked for a prescription (14 [40%] in 2009 and
22 [42%] in 2011).
Within the group of pharmacyworkers who did offer to sell mystery
clients a known medical abortion drug, an increase was observed in
2011 in the number who provided important information on medical
abortion; however, the provision of speciﬁc information was still
low overall (Table 3). None of the pharmacy workers who offered to
sell misoprostol in 2009 mentioned the correct number of tablets for
initial dosage (4 × 200 μg) the patient would need to induce a medicalTable 2
Behavior of pharmacyworkerswho offered to sell, or offered information about, a drug for
medical abortion.a
Pharmacy interaction 2009 study
visit (n = 35)
2011 study
visit (n = 53)
P value
Pharmacy workers referred client to a
health facility for medical abortion
3 (9) 14 (26) 0.0380b
Pharmacy workers referred client to
another pharmacy for medical abortion
8 (23) 7 (13) 0.2
Pharmacy worker mentioned/recommended
a valid medical abortion product
31 (89) 42 (79) 0.3
Pharmacy worker offered to sell the
client a valid medical abortion product
18 (51) 38 (72) 0.05b
Pharmacy worker mentioned/recommended
a drug but did not state the name
4 (11) 11 (21) 0.3
Pharmacy worker asked the client for a
prescription
14 (40) 22 (42) 0.9
Pharmacy worker asked about last
menses to assess gestational age
26 (74) 23 (43) 0.02b
a Values given as number (percentage) unless otherwise noted.
b Indicates a statistically signiﬁcant difference.abortion; in 2011, 8 (21%) of the pharmacy workers included in the
study did provide the correct dosage information (P = 0.0185). In
2011, all of the pharmacy workers who offered to sell medication to
themystery clients also provided one ormore pieces of correct informa-
tion about medical abortions, including information about normal
bleeding, pain, cramping, or when to seek care for emergency complica-
tions; this is in comparison with only 14 (78%) providers in 2009
that provided similar information (P b 0.001). Although not statistically
signiﬁcant, a decrease in the proportion of pharmacy workers who
clearly stated that misoprostol should not be taken if the woman is
more than 10–12 weeks pregnant (7 [39%] in 2009 compared with 10
[26%] in 2011) was observed.
4. Discussion
Between the two study years (2009 and 2011), pharmacy workers
exhibited increased awareness of misoprostol, less hostility, and more
willingness to provide information, sell medical abortion drugs and
provide referrals for facility-based care. Approximately 80% of pharma-
cy workers who did not offer to provide drugs or information directly
in 2011 still referred their clients to another health facility or pharma-
cy, indicating that there has been a shift toward better patient transfer
at this level of the health system. However, pharmacy workers con-
tinue to provide inadequate information to patients who purchase
misoprostol. Unsafe abortion-related morbidity is decreasing around
the globe [1–3,21]. Several theories exist about the causes of these
decreases but it is widely believed that greater evidence and informa-
tion regarding safermethods of self induction are at least partly respon-
sible [13,15,22,23]. The use of misoprostol, an inexpensive and widely
available drug, provides a safe and reliable option to reduce morbidity
arising from either self induction or from methods used by unskilled
induced-abortion practitioners. In a country where knowledge of legal
termination is still severely limited [24], pharmacy workers are impor-
tant middlemen; they are accessible and close to the communities
where they work.
Supported by similar studies, this research illustrates the limitations
of pharmacyworkers providingmedical abortionmedications for home
usewithout providing the essential information andhaving themost re-
cent scientiﬁc evidence available [25–27]. Effective training of pharma-
cy employees is important and can be a vital component of patient
access to safe medical abortion care [25]. Training should be focused
on critical areas, including the provision of basic information onmedical
abortion drugs (particularly misoprostol), referrals to safe induced-
abortion providers, the provision of services such as screening to deter-
mine a client’s eligibility for medical abortion, and informing clients
about the possible side effects, length of action, and danger signs.
Relaying essential information to patients, such as what “normal” and
“unusual” symptoms are, orwhen to seek help, is particularly important
in places like Zambia where internet connectivity is moderate to low
and there are nowritten package inserts for this off-label use. Addition-
ally, the use of phone lines as a method for pharmacists to access addi-
tional information on medical abortion should be explored. Without
adequate access to information about safe medical abortion, including
gestational limits, pharmacyworkers may not provide the correct med-
ication and dosage, potentially leading to delays in termination, which
may move patients outside the limits of medical abortion.
The mystery-client methodology provides a rare opportunity to
elicit information about behaviors related to a stigmatized procedure.
However, this means that each individual pharmacy worker’s position,
education, and previous exposure to medical abortion information are
unknown to the mystery client, and therefore, the researchers. As part
of the pilot study,manypharmacyworkers in these pharmacies had par-
ticipated in a 1-day training program (held in May–August 2009 and
May 2010) on compassionate treatment for people seeking information
about induced abortion, evidence-based regimens for medical abortion,
and the provision of referrals to facility-based induced-abortion services
Table 3
Behavior of pharmacy workers who offered to sell a valid medical abortion medication.a
Pharmacy interaction 2009 study visit
(n = 18)
2011 study visit
(n = 38)
P value
Pharmacy worker offered to sell misoprostol 18 (100) 31 (82) 0.05b
Pharmacy worker offered to sell the correct number of misoprostol pills (4 × 200 μg) 0 8 (21) 0.02b
Pharmacy worker stated that:
Length of pregnancy should be no longer than 10–12 wkc 7 (39) 10 (26) 0.3
There would be cramping for a few days, which would then stop 5 (28) 8 (21) 0.6
The patient would bleed for a few days, which would then stop NRd 31 (82) -
The patient should seek help only with a complication (bleeding being considered normal) NRd 8 (21) -
Pharmacy worker gave the mystery client one or more important pieces of information about medical abortione 14 (78) 38 (100) b0.001b
Abbreviation: NR, not reported.
a Values given as number (percentage) unless otherwise noted.
b Indicates a statistically signiﬁcant difference.
c The question asked in 2009 was whether the patient was at or beyond 12 weeks of pregnancy. The question asked in 2011 was whether the patient was at or beyond 10 weeks of
pregnancy.
d Some questions were added to the 2011 questionnaire; as such, they do not have an equivalent response for 2009.
e Important pieces of information included warning signs for complications as well as gestational limits for use of medical abortion drugs.
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effort to create an environment where international technical knowl-
edge was disseminated, many pharmacy workers were exposed to
short technical presentations on medical abortion drugs for gynecologi-
cal indications at professional association meetings and at the annual
workshops of the Pharmaceutical Society of Zambia, with a focus on in-
duced abortion. Some of the pharmacy workers who interacted with
mystery clients in 2011 likely attended a presentation or participated
in an intervention on mifepristone or misoprostol for gynecological
indications; however, it is impossible to know if the clients spoke to
these same participants or if information from that training event had
been relayed to other staff in the workplace. The results of the present
study may also be documenting a changing environment where infor-
mation on scientiﬁc advances is becoming available more rapidly. In
the present study, it is not possible to disentangle the effects of multiple
variables such as increased internet connectivity in Zambia, new global
clinical evidence, or participation in technical updates. The causal rela-
tionship may be cumulative.
Additionally, Zambian pharmacy workers and their pharmacies are
highly mobile, as demonstrated by numerous changes in shops and
stafﬁng in the 2 years between interviews. As such, listings conducted
in the two study years resulted in different records of functional shops
and changes in the locations of staff. Despite these challenges, this
study provides useful information on the attitudes and behaviors of
pharmacy workers in Zambia, showing decreased hostility towards in-
dividuals seeking information andmedication for inducing an abortion,
and increased willingness to provide information to patients. Using
mystery clients to explore the role of pharmacy workers’ practices in
the prevention, as well as the possible perpetuation, of unsafe abortion,
allows observations, and therefore recommendations, to be made re-
garding improving access to safe termination care and medications.
With the introduction of medical abortion in Zambia, information
about, and access to, safe abortion is increasing [14]. The national envi-
ronment is changing, and information about medical abortion and
access to legal medical abortion is increasing among healthcare pro-
viders and thewider public. The combination of policy changes allowing
pharmacists to sell medical abortion drugs, as well as adequate training
and access to information, could result in pharmacists being safe and re-
liable access points for medical abortion.
Pharmacy workers are an increasingly important cadre of ﬁrst-line
healthcare providers for abortion care, provided that they are armed
with appropriate knowledge and are allowed to use it. Simple,
straight forward updates on scientiﬁc advances in induced-abortion
care could help these frontline health workers dissuade women from
resorting to unsafe methods for self-induced termination and encour-
age the uptake of safer options to reduce morbidity and mortality
from unsafe abortions.Acknowledgements
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